Table 3.
Multiple treatment comparison of cohort network for endometrioma recurrence outcome
| Reference treatment | Risk ratio (95% CI) | |||||||
|---|---|---|---|---|---|---|---|---|
| Expectant management | Cyclic OC | Continuous OC | GnRHa | DNG | LNG‐IUS | GnRHa + OC | GnRHa + LNG‐IUS | |
| Expectant management | 8.7 | 0.35 (0.20–0.60) | 0.30 (0.11–0.77) | 1.03 (0.65–1.62) | 0.14 (0.05–0.43) | 0.05 (0.00–0.98) | 0.33 (0.15–0.71) | 0.15 (0.02–1.04) |
| Cyclic OC | 2.86 (1.66, 4.91) | 45.9 | 0.85 (0.33–2.19) | 2.93 (1.49–5.79) | 0.40 (0.12–1.36) | 0.15 (0.01–2.91) | 0.95 (0.38–2.33) | 0.43 (0.06–3.15) |
| Continuous OC | 3.37 (1.30, 8.70) | 1.18 (0.46–3.04) | 54.2 | 3.46 (1.26–9.49) | 0.47 (0.11–2.02) | 0.17 (0.01–3.77) | 1.11 (0.34–3.63) | 0.50 (0.06–4.27) |
| GnRHa | 0.97 (0.62, 1.53) | 0.34 (0.17–0.67) | 0.29 (0.11–0.79) | 7.3 | 0.14 (0.04–0.46) | 0.05 (0.00–0.95) | 0.32 (0.15–0.69) | 0.15 (0.02–1.01) |
| DNG | 7.16 (2.33, 22.01) | 2.51 (0.74–8.53) | 2.13 (0.49–9.14) | 7.36 (2.19–24.67) | 77.3 | 0.37 (0.02–8.60) | 2.37 (0.61–9.15) | 1.07 (0.11–10.02) |
| ‐IUS | 19.55 (1.02, 374.49) | 6.84 (0.34–136.21) | 5.80 (0.26–127.14) | 20.07 (1.05–383.44) | 2.73 (0.12–64.02) | 87.3 | 6.47 (0.37–111.99) | 2.93 (0.32–27.16) |
| GnRHa + OC | 3.02 (1.41, 6.50) | 1.06 (0.43–2.61) | 0.90 (0.28–2.93) | 3.10 (1.46–6.60) | 0.42 (0.11–1.63) | 0.15 (0.01–2.68) | 48.7 | 0.45 (0.08–2.68) |
| GnRHa + LNG‐IUS | 6.68 (0.96, 46.38) | 2.34 (0.32–17.21) | 1.98 (0.23–16.80) | 6.86 (0.99–47.42) | 0.93 (0.10–8.71) | 0.34 (0.04–3.17) | 2.21 (0.37–13.11) | 70.6 |
Each off‐diagonal cell contains RR (95% CI). Each diagonal cell contains SUCRA.
Bold indicates the values of sucra.